Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
A phase 2 trial of Endoscopic resection in Oesophageal squamous cell carcinoma, run by Chinese Academy of Medical Sciences, with a status the registry has not verified recently.
Overview
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma is a phase 2 interventional study registered as NCT04275986 by Chinese Academy of Medical Sciences, with 56 participants planned, started 2020-01-20 and due to reach its primary completion in 2024-01. Interventions recorded: Intensity modulated radiotherapy (IMRT), Chemotherapy. Conditions recorded: Esophageal Squamous Cell Carcinoma.
Linked to the technology Endoscopic resection because the registry's title names it ("endoscopic resection") and Oesophageal squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialStudy of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Shares Endoscopic resection (EMR / ESD), Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialA Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Shares Endoscopic resection (EMR / ESD) and the tag pipeline.
- TrialClinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialStudy of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Shares Oesophageal squamous cell carcinoma and the tag pipeline.
- TrialA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Shares Oesophageal squamous cell carcinoma and the tag pipeline.